Results 61 to 70 of about 20,079 (290)

Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trialResearch in context

The Lancet Regional Health. Europe
Summary: Background: Alcohol use disorder (AUD) is associated with an enormous burden of disease and cost to society. The dopamine deficiency hypothesis posits that negative reinforcement generated by a low brain dopamine state drives ethanol intake ...
Bo Söderpalm, Helga Lidö, Johan Franck, Anders Håkansson, Daniel Lindqvist, Markus Heilig, Joar Guterstam, Markus Samuelson, Barbro Askerup, Cecilia Wallmark-Nilsson, Andrea de Bejczy   +10 more
doaj   +1 more source

Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): A randomized controlled clinical trial.

PLoS ONE, 2020
IntroductionVarenicline tartrate is superior for smoking cessation to other tobacco cessation therapies by 52 weeks, in the outpatient setting. We aimed to evaluate the long-term (104 week) efficacy following a standard course of inpatient-initiated ...
Kristin V Carson-Chahhoud, Brian J Smith, Matthew J Peters, Malcolm P Brinn, Faisal Ameer, Kuljit Singh, Robert Fitridge, Simon A Koblar, Jim Jannes, Antony J Veale, Sharon Goldsworthy, Khin Hnin, Adrian J Esterman   +12 more
doaj   +1 more source

Nicotine addiction : a review [PDF]

, 2013
Nicotine, the major psychoactive compound in tobacco, acts as a potent addictive drug in humans. The addictive nature of nicotine leads to more than 6 million deaths a year.
Di Giovanni, Giuseppe, Vella, Jacob
core   +1 more source

Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors

Addiction, 2021
Background and Aims Analysed using classical frequentist hypothesis testing with alpha set to 0.05, the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) did not find enough evidence to reject the hypothesis of no difference in ...
E. Beard, S. Jackson, R. Anthenelli, N. Benowitz, Lisa B. St. Aubin, T. McRae, D. Lawrence, C. Russ, A. Krishen, A. E. Evins, R. West   +10 more
semanticscholar   +1 more source

VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY?

Рациональная фармакотерапия в кардиологии, 2015
The problem of varenicline use in patients with cardiovascular diseases is discussed. Results of large clinical trials and meta-analyses with varenicline have proven its high efficacy for treatment of nicotine addiction in adults and a small number of ...
Yu. V. Lukina, S. Yu. Martsevich
doaj   +3 more sources

Varenicline: A new pharmacotherapy for smoking cessation in primary care practice

South African Family Practice, 2011
Background: Cigarette smoking causes significant morbidity and mortality and is a major public health concern worldwide. Primary care doctors are in a unique position that enables them to promote smoking cessation, as smokers are more aware of their ...
N. Robson
doaj   +1 more source

The Food and Drug Administration and varenicline:should Risk Communication Be Improved? [PDF]

, 2016
[no ...
Davies, Neil M, Thomas, Kyla H
core   +1 more source

Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation

Preventive Medicine Reports, 2015
Objectives: A recent trial showed the clinical benefit of retreatment with varenicline in subjects failing on the initial treatment, or relapsing after initial success.
Lieven Annemans, Sophie Marbaix, Kristiaan Nackaerts, Pierre Bartsch   +3 more
doaj   +1 more source

Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo‐controlled studies of varenicline [PDF]

Journal of Diabetes Investigation, 2016
AbstractAims/IntroductionStopping smoking deserves high priority in preventing complications of diabetes; however, only sparse data are available regarding the efficacy of pharmacotherapy in smokers with diabetes. We assessed the efficacy and safety of varenicline in smokers with diabetes who participated in 15 double‐blind, randomized, placebo ...
David Lawrence, Serena Tonstad
openaire   +3 more sources

Impact of the disruption in supply of varenicline since 2021 on smoking cessation in England: A population study

Addiction
Background and aims Varenicline is one of the most effective smoking cessation treatments. Its supply in England was disrupted in July 2021 due to nitrosamine impurities found by its supplier, Pfizer.
Sarah E. Jackson, Jamie Brown, Harry Tattan-Birch, L. Shahab   +3 more
semanticscholar   +1 more source